

Genotype 1 Treatment Naïve No Cirrhosis Options

Elbasvir/Grazoprevir (Zepatier™) x 12 weeks¹

Glecaprevir/Pibrentasvir (Mavyret™) x 8 weeks

Ledipasvir/Sofosbuvir (Harvoni®) x 8-12 weeks²

Sofosbuvir/Velpatasvir (Epclusa®) x 12 weeks

¹ If genotype 1a, test for NS5A RAS first, if present, choose another regimen

² If < 6 million HCV RNA, non-Black, no HIV coinfection = 8 weeks

Genotype 1 Treatment Naïve Compensated Cirrhosis Options

Elbasvir/Grazoprevir (Zepatier™) x 12 weeks¹

Glecaprevir/Pibrentasvir (Mavyret™) x 12 weeks

Ledipasvir/Sofosbuvir (Harvoni®) x 12 weeks

Sofosbuvir/Velpatasvir (Epclusa®) x 12 weeks

¹ If genotype 1a, test for NS5A RAS first, if present, choose another regimen

Genotype 2 Treatment Naïve No Cirrhosis Options

Glecaprevir/Pibrentasvir (Mavyret™) x 8 weeks

Sofosbuvir/Velpatasvir (Epclusa®) x 12 weeks

Genotype 2 Treatment Naïve Compensated Cirrhosis Options

Glecaprevir/Pibrentasvir (Mavyret™) x 12 weeks

Sofosbuvir/Velpatasvir (Epclusa®) x 12 weeks

Genotype 3 Treatment Naïve No Cirrhosis Options

Glecaprevir/Pibrentasvir (Mavyret™) x 8 weeks

Sofosbuvir/Velpatasvir (Epclusa®) x 12 weeks

Genotype 3 Treatment Naïve Compensated Cirrhosis Options

Glecaprevir/Pibrentasvir (Mavyret™) x 12 weeks

Sofosbuvir/Velpatasvir (Epclusa®) x 12 weeks

Genotype 4 Treatment Naïve No Cirrhosis Options

Elbasvir/Grazoprevir (Zepatier™) x 12 weeks¹

Glecaprevir/Pibrentasvir (Mavyret™) x 8 weeks

Ledipasvir/Sofosbuvir (Harvoni®) x 12 weeks

Sofosbuvir/Velpatasvir (Epclusa®) x 12 weeks

Genotype 4 Treatment Naïve Compensated Cirrhosis Options

Elbasvir/Grazoprevir (Zepatier™) x 12 weeks

Glecaprevir/Pibrentasvir (Mavyret™) x 12 weeks

Ledipasvir/Sofosbuvir (Harvoni®) x 12 weeks

Sofosbuvir/Velpatasvir (Epclusa®) x 12 weeks

Genotype 5 or 6 Treatment Naïve No Cirrhosis Options

Glecaprevir/Pibrentasvir (Mavyret™) x 8 weeks

Ledipasvir/Sofosbuvir (Harvoni®) x 12 weeks

Sofosbuvir/Velpatasvir (Epclusa®) x 12 weeks

Genotype 5 or 6 Treatment Naïve Compensated Cirrhosis Options

Glecaprevir/Pibrentasvir (Mavyret™) x 12 weeks

Ledipasvir/Sofosbuvir (Harvoni®) x 12 weeks

Sofosbuvir/Velpatasvir (Epclusa®) x 12 weeks

Peginterferon/Ribavirin-Experienced, Genotype 1 Without Cirrhosis Options

Elbasvir/Grazoprevir (Zepatier™) x 12 weeks¹

Glecaprevir/Pibrentasvir (Mavyret™) x 8 weeks

Ledipasvir/Sofosbuvir (Harvoni®) x 12 weeks

Sofosbuvir/Velpatasvir (Epclusa®) x 12 weeks

¹ If genotype 1a, test for NS5A RAS first, if present, choose another regimen

Peginterferon/Ribavirin-Experienced, Genotype 1 With Compensated Cirrhosis Options

Elbasvir/Grazoprevir (Zepatier™) x 12 weeks¹

Glecaprevir/Pibrentasvir (Mavyret™) x 12 weeks

Sofosbuvir/Velpatasvir (Epclusa®) x 12 weeks

¹ If genotype 1a, test for NS5A RAS first, if present, choose another regimen

NS3 Protease Inhibitor (Telaprevir, Boceprevir or Simeprevir) + Peginterferon/Ribavirin-Experienced, Genotype 1 Without Cirrhosis Options

Glecaprevir/Pibrentasvir (Mavyret™) x 12 weeks

Ledipasvir/Sofosbuvir (Harvoni®) x 12 weeks

Sofosbuvir/Velpatasvir (Epclusa®) x 12 weeks

NS3 Protease Inhibitor (Telaprevir, Boceprevir or Simeprevir) + Peginterferon/Ribavirin-Experienced, Genotype 1 With Compensated Cirrhosis Options

Glecaprevir/Pibrentasvir (Mavyret™) x 12 weeks

Sofosbuvir/Velpatasvir (Epclusa®) x 12 weeks

Non-NS5A Inhibitor, Sofosbuvir-Containing Regimen- Experienced, Genotype 1 without Cirrhosis Options

Glecaprevir/Pibrentasvir (Mavyret™) x 12 weeks
regardless of subtype

Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi®) x 12 weeks
for genotype 1a patients

Sofosbuvir/Velpatasvir (Epclusa®) x 12 weeks for genotype
1b patients

Non-NS5A Inhibitor, Sofosbuvir-Containing Regimen- Experienced, Genotype 1 with Cirrhosis Options

Glecaprevir/Pibrentasvir (Mavyret™) x 12 weeks
regardless of subtype

Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi®) x 12 weeks
for genotype 1a patients

Sofosbuvir/Velpatasvir (Epclusa®) x 12 weeks for genotype
1b patients

NS5A Inhibitor DAA-Experienced Genotype 1-6 Patients Without Cirrhosis or With Compensated Cirrhosis

Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi®) x 12 weeks¹

¹ If genotype 3 with cirrhosis, the addition of weight-based ribavirin is recommended

Peginterferon/Ribavirin-Experienced, Genotype 2 Without Cirrhosis Options

Glecaprevir/Pibrentasvir (Mavyret™) x 8 weeks

Sofosbuvir/Velpatasvir (Epclusa®) x 12 weeks

Peginterferon/Ribavirin-Experienced, Genotype 2 With Compensated Cirrhosis Options

Glecaprevir/Pibrentasvir (Mavyret™) x 12 weeks

Sofosbuvir/Velpatasvir (Epclusa®) x 12 weeks

Sofosbuvir + Ribavirin-Experienced, Genotype 2 Without Cirrhosis or With Compensated Cirrhosis Options

Glecaprevir/Pibrentasvir (Mavyret™) x 12 weeks

Sofosbuvir/Velpatasvir (Epclusa®) x 12 weeks

Peginterferon/Ribavirin-Experienced, Genotype 3 Without Cirrhosis Options

Sofosbuvir/Velpatasvir (Epclusa[®]) x 12 weeks¹

¹ Baseline RAS testing for Y93H is recommended. If detected, choose a different regimen or add weight-based ribavirin.

Peginterferon/Ribavirin-Experienced, Genotype 3 Without Cirrhosis Options When Y93H Substitution Is Identified

Glecaprevir/Pibrentasvir (Mavyret™) x 16 weeks

Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi®) x 12 weeks

Peginterferon/Ribavirin-Experienced, Genotype 3 With Compensated Cirrhosis Options

Elbasvir/Grazoprevir (Zepatier™) plus Sofosbuvir 400mg x 12 weeks

Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi®) x 12 weeks

Peginterferon/Ribavirin-Experienced, Genotype 4 Without Cirrhosis Options

Elbasvir/Grazoprevir (Zepatier™) x 12 weeks¹

Glecaprevir/Pibrentasvir (Mavyret™) x 8 weeks

Ledipasvir/Sofosbuvir (Harvoni®) x 12 weeks

Sofosbuvir/Velpatasvir (Epclusa®) x 12 weeks

¹Only for patients who experienced virologic relapse, not treatment failure on Peg/Rib

Peginterferon/Ribavirin-Experienced, Genotype 4 With Compensated Cirrhosis Options

Elbasvir/Grazoprevir (Zepatier™) x 12 weeks¹

Glecaprevir/Pibrentasvir (Mavyret™) x 12 weeks

Sofosbuvir/Velpatasvir (Epclusa®) x 12 weeks

¹Only for patients who experienced virologic relapse, not treatment failure on Peg/Rib

Peginterferon/Ribavirin-Experienced, Genotype 5 or 6 Without Cirrhosis Options

Glecaprevir/Pibrentasvir (Mavyret™) x 8 weeks

Ledipasvir/Sofosbuvir (Harvoni®) x 12 weeks

Sofosbuvir/Velpatasvir (Epclusa®) x 12 weeks

¹ If genotype 1a, test for NS5A RAS first, if present, choose another regimen

Peginterferon/Ribavirin-Experienced, Genotype 5 or 6 With Compensated Cirrhosis Options

Glecaprevir/Pibrentasvir (Mavyret™) x 12 weeks

Ledipasvir/Sofosbuvir (Harvoni®) x 12 weeks

Sofosbuvir/Velpatasvir (Epclusa®) x 12 weeks